Since then, ST6Gal1-mediated activation of EGFR has been identified to influence survival, proliferation, apoptosis evasion, chemotherapy resistance, invasion and metastasis in a host of cancers including colorectal cancer (Liu et al., 2011b; Chang et al., 2018; Rodrigues et al., 2021) ovarian cancer (Schultz et al., 2013; Britain et al., 2018; Rao et al., 2022), and pancreatic ductal adenocarcinoma (Chakraborty et al., 2018). This evidence concerns the gene ST6GAL1 and ovarian carcinoma.